Drug Information

Drug General Information
Drug ID
D08VSI
Former ID
DAP001447
Drug Name
Revolade/Promacta
Drug Type
Small molecular drug
Indication Idiopathic thrombocytopenic purpura [ICD9: 287.31; ICD10:D69.3] Approved [538590]
Chronic liver disease; HCV induced thrombocytopaenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] Phase 3 [538590]
Oncology-related thrombocytopaenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] Phase 2 [538590]
Company
GSK
Structure
Download
2D MOL

3D MOL
Formula
C22H31Cl
Canonical SMILES
C1CCCC(CC1)CC=CC2=CC(=C(C=C2)C3CCCCC3)Cl
InChI
1S/C22H31Cl/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20/h8,12,15-18,20H,1-7,9-11,13-14H2/b12-8-
InChIKey
NDXQJQCGBAIFER-WQLSENKSSA-N
CAS Number
CAS 139592-99-7
PubChem Compound ID
6913084
PubChem Substance ID
43525799, 80923035, 114777638, 134338647
Target and Pathway
Target(s) Thrombopoietin Receptor Target Info Agonist [550963]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
WikiPathways Platelet Aggregation (Plug Formation)
References
Ref 538590FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022291.
Ref 550963Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.